TABLE OF CONTENTS
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST AND AFRICA PCR MULTIPLEX ASSAYS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 MIDDLE EAST AND AFRICA PCR MULTIPLEX ASSAYS MARKET: GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7 DBMR MARKET POSITION GRID
2.8 MARKET APPLICATION COVERAGE GRID
2.9 DBMR VENDOR SHARE ANALYSIS
2.10 MULTIVARIATE MODELING
2.11 PRODUCTS LIFELINE CURVE
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.1.1 TECHNOLOGICAL ADVANCEMENTS OF PCR MULTIPLEX ASSAYS
3.1.2 INTRODUCTION OF NOVEL AUTOMATED SYSTEMS
3.1.3 GROWING RESEARCH AND DEVELOPMENT FOR DRUG DISCOVERY
3.1.4 USE OF MULTIPLEX ASSAYS IN COMPANION DIAGNOSTICS
3.2 RESTRAINTS
3.2.1 HIGH COST OF THE MULTIPLEX ASSAYS
3.2.2 STRINGENT REGULATIONS AND STANDARDS
3.3 OPPORTUNITIES
3.3.1 GROWING VALIDATION OF BIOMARKERS IN MOLECULAR AND PROTEIN DIAGNOSTICS
3.3.2 BUSINESS EXPANSION FOR DEVELOPMENT OF PCR MULTIPLEX ASSAYS
3.4 CHALLENGE
3.4.1 LACK OF PROFICIENT LABOUR TO HANDLE ADVANCED PROCEDURES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
6 MIDDLE EAST AND AFRICA PCR MULTIPLEX ASSAYS MARKET, BY PRODUCTS & SERVICES
6.1 OVERVIEW
6.2 REAGENTS & CONSUMABLES
6.3 INSTRUMENTS & ACCESSORIES
6.4 SOFTWARE AND SERVICES
7 MIDDLE EAST AND AFRICA PCR MULTIPLEX ASSAYS MARKET, BY APPLICATION
7.1 OVERVIEW
7.2 CLINICAL DIAGNOSTICS
7.2.1 CANCER
7.2.2 CARDIOVASCULAR DISEASES
7.2.3 RESPIRATORY DISEASES
7.2.4 METABOLISM & ENDOCRINOLOGY DISORDERS
7.2.5 NERVOUS SYSTEM DISORDERS
7.2.6 AUTOIMMUNE DISEASES
7.2.7 ALLERGIES
7.2.8 OTHERS
7.3 RESEARCH & DEVELOPMENT
7.3.1 DRUG DISCOVERY & DEVELOPMENT
7.3.2 BIOMARKER DISCOVERY & VALIDATION
8 MIDDLE EAST AND AFRICA PCR MULTIPLEX ASSAYS MARKET, BY END USER
8.1 OVERVIEW
8.2 HOSPITALS
8.3 CLINICAL LABORATORIES
8.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
8.5 RESEARCH INSTITUTES
8.6 OTHERS
?
9 MIDDLE EAST AND AFRICA PCR MULTIPLEX ASSAYS MARKET, BY GEOGRAPHY
9.1 MIDDLE EAST & AFRICA
9.1.1 SOUTH AFRICA
9.1.2 REST OF MIDDLE EAST & AFRICA
9.1.3 EGYPT
9.1.4 SAUDI ARABIA
9.1.5 UNITED ARAB EMIRATES
9.1.6 ISRAEL
10 MIDDLE EAST AND AFRICA PCR MULTIPLEX ASSAYS MARKET, COMPANY LANDSCAPE
10.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
11 SWOT ANALYSIS
11.1 STRENGTH: - SIGNIFICANT INCREASING SHARES IN MARKET FOCUSED SEGMENT
11.2 STRENGTH: - STRONG MIDDLE EAST AND AFRICA PRESENCE AND MARKET SHARE
11.3 WEAKNESS: - PRODUCT RECALL
11.4 OPPORTUNITY: - STRATEGIC INVESTMENTS
11.5 THREAT: - STIFF COMPETITION
12 COMPANY PROFILES
12.1 F. HOFFMANN-LA ROCHE LTD.
12.1.1 COMPANY SNAPSHOT
12.1.2 REVENUE ANALYSIS
12.1.3 COMPANY SHARE ANALYSIS
12.1.4 PRODUCT PORTFOLIO
12.1.5 RECENT DEVELOPMENTS
12.2 HOL0GIC INC
12.2.1 COMPANY SNAPSHOT
12.2.2 REVENUE ANALYSIS
12.2.3 COMPANY SHARE ANALYSIS
12.2.4 PRODUCT PORTFOLIO
12.2.5 RECENT DEVELOPMENTS
12.3 LUMINEX CORPORATION.
12.3.1 COMPANY SNAPSHOT
12.3.2 REVENUE ANALYSIS
12.3.3 COMPANY SHARE ANALYSIS
12.3.4 PRODUCT PORTFOLIO
12.3.5 RECENT DEVELOPMENTS
?
12.4 BECTON, DICKINSON AND COMPANY
12.4.1 COMPANY SNAPSHOT
12.4.2 REVENUE ANALYSIS
12.4.3 COMPANY SHARE ANALYSIS
12.4.4 PRODUCT PORTFOLIO
12.4.5 RECENT DEVELOPMENTS
12.5 ABBOTT
12.5.1 COMPANY SNAPSHOT
12.5.2 REVENUE ANALYSIS
12.5.3 PRODUCT PORTFOLIO
12.5.4 RECENT DEVELOPMENTS
12.6 AGENA BIOSCIENCE, INC
12.6.1 COMPANY SNAPSHOT
12.6.2 PRODUCT PORTFOLIO
12.6.3 RECENT DEVELOPMENT
12.7 AGILENT TECHNOLOGIES, INC
12.7.1 COMPANY SNAPSHOT
12.7.2 REVENUE ANALYSIS
12.7.3 PRODUCT PORTFOLIO
12.7.4 RECENT DEVELOPMENT
12.8 BIO-RAD LABORATORIES, INC.
12.8.1 COMPANY SNAPSHOT
12.8.2 REVENUE ANALYSIS
12.8.3 PRODUCT PORTFOLIO
12.8.4 RECENT DEVELOPMENTS
12.9 BIOMeRIEUX SA
12.9.1 COMPANY SNAPSHOT
12.9.2 REVENUE ANALYSIS
12.9.3 PRODUCT PORTFOLIO
12.9.4 RECENT DEVELOPMENTS
12.10 BIOTEK INSTRUMENTS, INC.
12.10.1 COMPANY SNAPSHOT
12.10.2 PRODUCT PORTFOLIO
12.10.3 RECENT DEVELOPMENT
12.11 DIASORIN S.P.A
12.11.1 COMPANY SNAPSHOT
12.11.2 REVENUE ANALYSIS
12.11.3 PRODUCT PORTFOLIO
12.11.4 RECENT DEVELOPMENT
?
12.12 EUROFINS SCIENTIFIC
12.12.1 COMPANY SNAPSHOT
12.12.2 REVENUE ANALYSIS
12.12.3 PRODUCT PORTFOLIO
12.12.4 RECENT DEVELOPMENT
12.13 ILLUMINA, INC.
12.13.1 COMPANY SNAPSHOT
12.13.2 REVENUE ANALYSIS
12.13.3 PRODUCT PORTFOLIO
12.13.4 RECENT DEVELOPMENT
12.14 OLINK
12.14.1 COMPANY SNAPSHOT
12.14.2 PRODUCT PORTFOLIO
12.14.3 RECENT DEVELOPMENT
12.15 PATHONOSTICS B.V.
12.15.1 COMPANY SNAPSHOT
12.15.2 PRODUCT PORTFOLIO
12.15.3 RECENT DEVELOPMENT
12.16 PERKINELMER INC.
12.16.1 COMPANY SNAPSHOT
12.16.2 REVENUE ANALYSIS
12.16.3 PRODUCT PORTFOLIO
12.16.4 RECENT DEVELOPMENT
12.17 QIAGEN
12.17.1 COMPANY SNAPSHOT
12.17.2 REVENUE ANALYSIS
12.17.3 PRODUCT PORTFOLIO
12.17.4 RECENT DEVELOPMENTS
12.18 QUEST DIAGNOSTICS INCORPORATED
12.18.1 COMPANY SNAPSHOT
12.18.2 REVENUE ANALYSIS
12.18.3 PRODUCT PORTFOLIO
12.18.4 RECENT DEVELOPMENT
12.19 RANDOX LABORATORIES LTD.
12.19.1 COMPANY SNAPSHOT
12.19.2 PRODUCT PORTFOLIO
12.19.3 RECENT DEVELOPMENT
?
12.20 SEEGENE INC.
12.20.1 COMPANY SNAPSHOT
12.20.2 REVENUE ANALYSIS
12.20.3 PRODUCT PORTFOLIO
12.20.4 RECENT DEVELOPMENT
12.21 SIEMENS
12.21.1 COMPANY SNAPSHOT
12.21.2 REVENUE ANALYSIS
12.21.3 PRODUCT PORTFOLIO
12.21.4 RECENT DEVELOPMENTS
12.22 SYSMEX CORPORATION
12.22.1 COMPANY SNAPSHOT
12.22.2 REVENUE ANALYSIS
12.22.3 PRODUCT PORTFOLIO
12.22.4 RECENT DEVELOPMENTS
12.23 THERMO FISHER SCIENTIFIC INC.
12.23.1 COMPANY SNAPSHOT
12.23.2 REVENUE ANALYSIS
12.23.3 PRODUCT PORTFOLIO
12.23.4 RECENT DEVELOPMENT
13 CONCLUSION
14 QUESTIONNAIRE
15 RELATED REPORTS